175 related articles for article (PubMed ID: 35668332)
1. Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
Ryspayeva D; Halytskiy V; Kobyliak N; Dosenko I; Fedosov A; Inomistova M; Drevytska T; Gurianov V; Sulaieva O
Discov Oncol; 2022 Jun; 13(1):43. PubMed ID: 35668332
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
[TBL] [Abstract][Full Text] [Related]
3. Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer.
Todorova VK; Byrum SD; Gies AJ; Haynie C; Smith H; Reyna NS; Makhoul I
Curr Oncol; 2022 Jan; 29(2):613-630. PubMed ID: 35200555
[TBL] [Abstract][Full Text] [Related]
4. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.
McGuire A; Casey MC; Waldron RM; Heneghan H; Kalinina O; Holian E; McDermott A; Lowery AJ; Newell J; Dwyer RM; Miller N; Keane M; Brown JAL; Kerin MJ
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645898
[TBL] [Abstract][Full Text] [Related]
5. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
6. Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus.
Zhang S; Guo LJ; Zhang G; Wang LL; Hao S; Gao B; Jiang Y; Tian WG; Cao XE; Luo DL
Tumour Biol; 2016 Aug; 37(8):11057-63. PubMed ID: 26897751
[TBL] [Abstract][Full Text] [Related]
7. Circulating miR-326 could serve as a predictive biomarker for response to neoadjuvant chemotherapy in locally advanced cervical cancer.
Zou K; Yang E; Cui T; Li Z
Front Oncol; 2022; 12():1036710. PubMed ID: 36439477
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
[TBL] [Abstract][Full Text] [Related]
9. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
Zhao FL; Dou YC; Wang XF; Han DC; Lv ZG; Ge SL; Zhang YK
Mol Biol Rep; 2014 Sep; 41(9):5913-22. PubMed ID: 25103018
[TBL] [Abstract][Full Text] [Related]
10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
11. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-124a and microRNA-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa.
Deng G; Kakar S; Kim YS
Oncol Lett; 2011 Jan; 2(1):175-180. PubMed ID: 22870149
[TBL] [Abstract][Full Text] [Related]
13. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
14. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
[TBL] [Abstract][Full Text] [Related]
15. Correlations of microRNA-124a and microRNA-30d with clinicopathological features of breast cancer patients with type 2 diabetes mellitus.
Han YL; Cao XE; Wang JX; Dong CL; Chen HT
Springerplus; 2016; 5(1):2107. PubMed ID: 28066696
[TBL] [Abstract][Full Text] [Related]
16. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
17. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
18. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
[TBL] [Abstract][Full Text] [Related]
19. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
